RADA to Participate in Upcoming Virtual Investor Conferences

NETANYA, Israel, Jan. 04, 2021 (GLOBE NEWSWIRE) — RADA Electronic Industries Ltd. (Nasdaq: RADA) today announced that it will participate in a number of upcoming virtual investor conferences and investor meetings in the coming weeks.

On Thursday, January 14, 2021, management will participate in the 23rd Annual Needham Virtual Growth conference. Management will be publicly presenting the Company presentation at 12:30pm ET via the Needham conference portal and will be meeting virtually with investors on a one-on-one basis throughout the day.

On Thursday, February 4, 2021, management will participate in the AGP Virtual Emerging Growth Technology Conference and will be meeting virtually with investors on a one-on-one basis throughout the day.

On Thursday, February 11, 2021, management will participate in the Cowen 42nd Annual Aerospace/Defense & Industrials Conference. Management will be publicly presenting the Company presentation at 8:30am ET via the Cowen conference portal and will be meeting virtually with investors on a one-on-one basis throughout the day.

Investors wishing to participate in any of the above events and meet virtually with management, should be in touch with their contact at the respective organizing banks or contact RADA’s investor relations team.


About RADA

RADA is a global defense technology company focused on proprietary radar solutions and legacy avionics systems. The Company is a leader in mini-tactical radars, serving attractive, high-growth markets, including active military protection, counter-UAS, critical infrastructure protection and border surveillance.

Company Contact:

Avi Israel (CFO)
Tel: +972-76-538-6200
[email protected]
www.rada.com

IR Contact

GK Investor Relations
Ehud Helft, Partner
Tel: 1 617 318 3096
[email protected]



CIMC Enric’s Subsidiary Deploys Vaccine Storage Market To Carry out R&D of Cryogenic Liquid Nitrogen Biological Container

PR Newswire

SHENZHEN, China, Jan. 4, 2021 /PRNewswire/ — CIMC Enric Holdings Limited (“CIMC Enric” or “the Company“, SEHK stock code: 3899.HK), announced that its subsidiary Zhangjiagang CIMC Sanctum Cryogenic Equipment Co., Ltd (“CIMC Sanctum“) recently started R&D of liquid nitrogen biological containers for long-term cryogenic storage of vaccines, stem cells, plasma, semen, embryos and various tissues and organs for the needs of the biomedical industry.

The liquid nitrogen biological container will be designed based on the GB14174 “large-caliber liquid nitrogen container” standard. Upon successful development, the equipment will adopt advanced technologies such as high vacuum multilayer insulation, electronic temperature control, and liquid nitrogen dispersion to make the intelligent cooling and constant temperature process uniform and stable. It is expected that the product will provide immersion storage and vapor phase storage in two ways, providing users with a fully automatic, safe and reliable cryogenic liquid nitrogen storage system.

The equipment is specifically developed for cryogenic storage of biological samples. In the future, the finished equipment is expected to have many outstanding features including small size, large storage as well as superior temperature uniformity and stability. The equipment will have advanced temperature and liquid level monitoring, an alarm system and a remote monitoring program that can be connected to the Internet. The equipment body will be made of high-quality stainless steel with its own moving and braking device. It will support full-opening and has large opening for sample storage. The equipment is designed with lowest-possible liquid nitrogen consumption for large sample storage capacity and better cost savings per unit sample.

It is worth noting that when the equipment is stored in the gas phase, the temperature difference in the entire storage area will not exceed 10°C, and the minimum temperature at the top of the design freezer shelf can reach -190°C, which will perfectly fit the temperature requirement of 20°C to -80°C for the current COVID-19 vaccine developed by global pharmaceutical companies. The equipment can also effectively meet the cryogenic storage requirements of various biological samples by most drug distribution companies, hospitals, pharmacies, disease control centers, testing centers, biopharmaceutical companies, scientific research institutes and other institutions. The equipment will provide a strong protection for future scientific research, disease diagnosis and treatment.

Mr. Yang Xiaohu, General Manager and Executive Director of CIMC Enric, commented, “The mass production of domestic and foreign vaccines is just around the corner, but the cold chain storage and transportation of vaccines is still one of the challenges that countries need to overcome together. As the industry leader, the Company has rich experience and advanced technology in the field of cryogenic storage, transportation and smart temperature control. The Company also sees the demand for biomedical cryogenic storage equipment derived from the epidemic and has begun to increase related R&D investment with the vision to establish a more complete vaccine cold chain storage and transportation system.”

Mr. Xu Zhiquan, General Manager and Director of CIMC Sanctum emphasized, “As CIMC Enric’s backbone subsidiary specialized in cryogenic equipment manufacturing, CIMC Sanctum has powerful R&D institutes including a National Post-Doctoral Scientific Research Workstation, the Technology Centre of Jiangsu Province, and the Cryogenic Storage and Transport Equipment Engineering Technology Research Centre of Jiangsu Province. Cryogenic vaccine storage containers and the Company’s current cryogenic storage and transportation equipment share similar technologies. CIMC Sanctum has the ability and strength to develop cryogenic storage equipment for biomedical products. Biomedical cryogenic storage equipment is the infrastructure of the medical testing centers. The outbreak of COVID-19 has revealed the huge gap in related equipment. The Company’s new deployment is to meet with the urgent needs of China and the world to transform the testing capabilities and cryogenic storage of the new COVID-19 vaccine, to explore the huge potential of biomedical cryogenic storage industry and generating more diversified income.”


About CIMC Enric Holdings Limited
 

CIMC ENRIC Holdings Limited is engaged in the design, development, manufacturing, engineering and sales, as well as provision of technical maintenance services for, a wide range of transportation, storage and processing equipment used in the clean energy, chemical & environmental, liquid food industries. The company has set up a comprehensive marketing network with global coverage. After nearly ten years of steady development, the company is now the world’s top player in both production and sales of ISO liquid tanks as well as high pressure gas storage and transportation equipment, and China’s top player in cryogenic facilities, with regard to the production and sales volumes of CNG, LNG and LPG energy storage and transportation equipment. For further information, please visit: http://www.enricgroup.com/en/


About Zhangjiagang CIMC Sanctum Cryogenic Equipment Co., Ltd

CIMC Sanctum, a subsidiary of CIMC Enric, is a leading cryogenic equipment manufacturer and system solution provider, headquartered in Zhangjiagang City, Jiangsu Province. It is engaged in design, production, sales and related technical services of cryogenic storage tanks, lorry tankers, tank containers and cryogenic cylinders for hazardous chemical substance such as liquid oxygen, liquid nitrogen, liquid argon, liquid carbon dioxide and liquefied natural gas (LNG). It also undertakes construction as general contractor for cryogenic engineering projects such as LNG/L-CNG refueling stations, LNG gasification stations, flat bottom tanks, cluster tanks, spherical tanks, refuelling for ships, transportation and fuel gas supply system. The equipment manufactured by CIMC Sanctum have won a number of national awards. The company has been widely recognized by well-known clients both in China and abroad for its advanced technology, excellent quality and outstanding after-sales service. For further information, please visit http://www.sdy-cn.com/Home.html.

 

Cision View original content:http://www.prnewswire.com/news-releases/cimc-enrics-subsidiary-deploys-vaccine-storage-market-to-carry-out-rd-of-cryogenic-liquid-nitrogen-biological-container-301200077.html

SOURCE CIMC

Mexus Increasing Gold Production Capacity at Santa Elena Mine

CABORCA, Mexico, Jan. 04, 2021 (GLOBE NEWSWIRE) — Mexus Gold US (OTCQB: MXSG) (“Mexus” or the “Company) released an update on mining operations at its Santa Elena mine located in Caborca, Sonora State, MX. Over the past few months the company has replaced the original heap leach pad and added mineralized material from the Mexus III pit. This area has an impressive geological structure as a mixed oxide thrust shear zone with shattered quartz fragments and some quartz stock work near the major quartz vein. An additional 5000 tons of this material will be crushed and ready to leach by January 5th. This material runs .9 to 1.2 gpt Au head ore with pregnant solution returning to the pond expected at .29 to .36 gpt Au to start. This additional tonnage will increase our pregnant solution flow from 27gpm to 45gpm with 100gpm expected to be reached by February 1st. As additional tons of mineralized material are placed on the pad the square feet of surface area increases allowing for additional cyanide solution to leach. The company expects to reach 350gpm by mid-2021.    

“As 2021 begins I’m reminded of the great opportunity we have at the Santa Elena property. Mexus controls over 20,000 acres with half being on the Mojave Sonora Mega Shear Zone. Fresnillo’s Noche Buena and La Herradura mines, which neighbors Mexus property, are mining this same system. The company will continue to keep all options open for further exploration and development of our property which could include partnership with other mining companies to maximize shareholder return.” added Mexus CEO Paul Thompson, Sr.

About Mexus Gold US

Mexus Gold US is an American based mining company with holdings in Mexico.  The fully owned Santa Elena mine is located 54km NW of Caborca, Mexico.  Mexus also owns rights to the Ures property located 80km N of Hermosillo, Mexico. This property contains 6900 acres and has both gold and copper on the property.   Founded in 2009, Mexus Gold US is committed to protecting the environment, mine safety and employing members of the communities in which it operates.

For more information on Mexus Gold US, visit www.mexusgoldus.com

Mexus Gold US (775) 721-9960 Paul Thompson Sr

Cautionary Statement

Forward looking Statement: Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.



Northern Data: Existing Bitcoin Mining Customer Expands Contract Volume by More Than 200 MW

Northern Data: Existing Bitcoin Mining Customer Expands Contract Volume by More Than 200 MW

  • The rise of Bitcoin catapults customer demand to new heights
  • Northern Data participates in the positive bitcoin price development through performance-based component of customer fees
  • Accelerated expansion of up to five new data center locations

 

FRANKFURT AM MAIN, Germany–(BUSINESS WIRE)–
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), a leading provider of high-performance computing (HPC) solutions, can announce the extension of a customer contract of a volume of ASIC chips worth USD 100 million. The existing customer, from the bitcoin mining sector, is making use of an extension option, which it drew at the end of the year. The USD 100 million order volume of ASIC chips corresponds to an additional capacity of more than 200 MW, which will be allocated to Northern Data’s up-to-five new Scandinavian and Canadian data center locations, among others. The expansion of these new HPC data centers is being accelerated due to the massive growth in customer demand.

In addition to the expanded order volume, Northern Data also benefits from a performance-based remuneration component with this customer on top of the basic fee, meaning that Northern Data participates in the positive development of the bitcoin price. This additional revenue driver is not included in the Company’s forecast for 2021 and therefore represents additional significant upside potential. As recently as mid-December, the Company forecast revenues of EUR 350 million to EUR 400 million with EBITDA of EUR 100 million to EUR 125 million for the 2021 financial year, which has just begun.

The need for bitcoin mining infrastructure is growing rapidly, especially due to the fast-developing acceptance of bitcoin as a new asset class. With around eight years of experience in the field of infrastructure for HPC applications such as bitcoin mining, Northern Data’s offering is built upon many proprietary technologies. These include an innovative air-cooling system developed in-house, as well as artificial intelligence for controlling and optimizing the operation of the HPC hardware. These solutions enable Northern Data to deliver capacity to customers in record time.

CEO Aroosh Thillainathan comments, “The upsizing of this customer order is a great testament to our technology-leading solutions for bitcoin mining infrastructure. With this customer, we will directly participate in the rising bitcoin price and thus have an additional upside that we had not previously factored into our forecast for 2021. But bitcoin mining is only one of the many growth drivers in our business: In addition to the accelerated expansion of our bitcoin mining activities, we are also benefiting from rapidly developing customer demand in other application areas of high-performance computing. Just in early December, we started commissioning our GPU cluster, which will allow us to benefit from the exploding demand for HPC services for artificial intelligence, deep learning, research and rendering.”

About Northern Data

Northern Data AG develops and operates global infrastructure solutions in the field of high-performance computing (HPC). With its customized solutions, the company provides the HPC applications in areas such as bitcoin mining, artificial intelligence, blockchain, Big Data analytics, IoT and rendering. The international company is now a leading provider of HPC solutions worldwide. Northern Data offers its HPC solutions both in large, stationary data centers and in mobile high-tech data centers that can be set up at any location worldwide. The company combines self-developed software and hardware with intelligent concepts for a sustainable energy supply. The Northern Data Group currently employs around 150 people.

Disclaimer

This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for securities of Northern Data AG, nor does it constitute a securities prospectus of Northern Data AG. The information contained in this press release is not intended to be the basis for any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As in all business and investment matters, please consult qualified professional advice.

Language:

English

Company:

Northern Data AG

Thurn-und-Taxis-Platz 6

60313 Frankfurt/Main

Germany

Phone:

+49 69 34 87 52 25

E-mail:

[email protected]

Internet:

www.northerndata.de

ISIN:

DE000A0SMU87

WKN:

A0SMU8

Listed:

Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Hanover, Munich (m:access), Stuttgart, Tradegate Exchange

 

Press contact

Northern Data AG

Dr. Hans Joachim Dürr

Head of Corporate Communications

Thurn-und-Taxis-Platz 6

60313 Frankfurt

E-Mail: [email protected]

Telefon: +49 69 348 752 89

Investor Relations

Sven Pauly

E-Mail: [email protected]

Telephone: +49 89 125 09 03 30

KEYWORDS: Germany Europe

INDUSTRY KEYWORDS: Professional Services Data Management Technology Software Finance Internet Hardware

MEDIA:

Voyager Digital to Present at Upcoming Investor Conferences

PR Newswire

CSE: VYGR
OTCQB: VYGVF
Borse Frankfurt: UCD2


Management will present at the SNN Network Canada Virtual Conference, Noble Capital Small and Microcap Investor Conference and the A.G.P. Virtual Emerging Growth Technology Conference

NEW YORK, Jan. 4, 2021 /PRNewswire/ – Voyager Digital  Ltd. (“Voyager” or the “Company”) (CSE: VYGR) (OTCQB: VYGVF) (FRA: UCD2), a publicly-traded, licensed crypto-asset broker that provides investors with a turnkey solution to trade crypto assets, today announced that its CEO and Co-founder, Steve Ehrlich, will present and be available to meet with investors at the following upcoming investor conferences:



Date



Presentation Time (EST)



Registration Link



SNN Network Canada Virtual Conference

Jan. 7

1:00 PM



Register



Noble Capital Markets Seventeenth Annual Small & Microcap Investor Conference

Jan.  19-20

TBD


Register



A.G.P. Virtual Emerging Growth Technology Conference

Feb 4

1x1s

 Information

Management will provide an overview of the Company’s business during each presentation as well as progress updates. The Company will also be available for one-on-one meetings with investors who are registered to attend the conferences. 

“Voyager is excited to update investors with our recent progress,” said Steve Ehrlich, Co-founder and CEO of Voyager. “Our platform is seeing unprecedented growth as digital assets are increasingly utilized by the mainstream for investment and payment processing. We recently announced our assets under management have surpassed $200 million, up from $5 million just a year ago. This speaks to the strength of Voyager’s easy-to-use trading platform, which enables investors to trade commission-free on 55 digital assets.” 

If you are an institutional investor and would like to attend the Company’s presentation, please click on the above links to register for each individual conference.

For more information on Voyager Digital, please visit https://www.investvoyager.com. The Voyager app is available for Android and iPhone.

About Voyager Digital Ltd.
Voyager Digital Ltd. is a crypto-asset broker that provides retail and institutional investors with a turnkey solution to trade crypto assets. Voyager offers customers best execution and safe custody on a wide choice of popular crypto-assets. Voyager was founded by established Wall Street and Silicon Valley entrepreneurs who teamed to bring a better, more transparent and cost-efficient alternative for trading crypto-assets to the marketplace. Please visit us at https://www.investvoyager.com for more information and to review the latest Corporate Presentation.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. No securities regulatory authority has either approved or disapproved of the contents of this press release.

Cautionary Statement Regarding Forward-Looking Information: The forward-looking statements contained herein are made as of the date of this release and, other than as required by applicable securities laws, the Company does not assume any obligation to update or revise it to reflect new events or circumstances. The forward-looking statements contained in this release are expressly qualified by this cautionary statement.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/voyager-digital-to-present-at-upcoming-investor-conferences-301199997.html

SOURCE Voyager Digital (Canada) Ltd.

ERYTECH to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

ERYTECH to Present at the LifeSci Partners
10th Annual Healthcare Corporate Access Event

Lyon (France) and Cambridge, MA (U.S.), January 4, 2021

ERYTECH Pharma
(Nasdaq & Euronext: ERYP),
a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today
that CEO, Gil Beyen, will present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Wednesday, January 6th at 9am EST /2pm GMT /3pm CET. The format will be a virtual presentation with the opportunity for Q&A at the conclusion.

The event will be held virtually, with all corporate and institutional participants joining remotely. Investors interested can pre-register for the January 6th 9am Eastern Time corporate presentation with the following registration link: http://lifesci.events/LifeSci2021.  
A webcast of the event will be available on ERYTECH’s website at https://erytech.com/investors/webcast/

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia was recently completed in the Nordic countries of Europe. Eryaspase is not approved in any country.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.            
For more information, please visit www.erytech.com      

Forward-looking information

This press release contains forward-looking statements including but not limited to statements with respect to the clinical development plans of eryaspase; the potential indications for and benefits of eryaspase; statements relating to the TRYbeCA-1 clinical trial, including the timeline for patient enrollment as well as expected timing of the availability of results and interim superiority analysis; potential impacts on the Company’s clinical trials, including TRYbeCA-1 clinical trial, due to the coronavirus (COVID-19) pandemic such as delays in regulatory review, manufacturing and supply chain interruptions; and the overall impact of the COVID-19 pandemic on the global healthcare system as well as the Company’s business, financial condition and results of operations. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH’s control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results and timeline may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2019 Document d’Enregistrement Universel filed with the AMF on March 18, 2020 and in the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2020 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. In addition, the COVID-19 pandemic and the associated containment efforts have had a serious adverse impact on the economy, the severity and duration of which are uncertain. Government stabilization efforts will only partially mitigate the consequences. The extent and duration of the impact on the Company’s business and operations is highly uncertain, and that impact includes effects on its clinical trial operations and supply chain. Factors that will influence the impact on the Company’s business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. The pandemic could have a material adverse impact on the Company’s business, operations and financial results for an extended period of time.

CONTACTS 

ERYTECH                            

Eric Soyer

CFO & COO
LifeSci Advisors, LLC

Investor Relations
Corey Davis, Ph.D.

 

NewCap

Mathilde Bohin /
Louis-Victor Delouvrier


Investor relations
Nicolas Merigeau
Media relations

 

+33 4 78 74 44 38
[email protected]

 

 

+1 (212) 915 – 2577
[email protected]

 

+33 1 44 71 94 94
[email protected]

Attachment



Ahold Delhaize commences 2021 share buyback program

Zaandam, the Netherlands, January 4, 2021 – Ahold Delhaize today commences the €1 billion share buyback program announced on November 4, 2020 and expects to complete the program before the end of 2021.
Maintaining a balanced approach between funding growth in key channels and returning excess liquidity to shareholders is part of Ahold Delhaize’s financial framework to support its Leading Together strategy. The purpose of the program is to reduce the capital of Ahold Delhaize, by cancelling all or part of the common shares acquired through the program.
The program will be executed by intermediaries allowing the execution of share repurchases in the open market during open and closed periods. The program will be executed within the limits of relevant laws and regulations, the existing authority granted at Ahold Delhaize’s 2020 annual general meeting of shareholders on April 8, 2020 and the authority (if granted) by the annual general meeting on April 14, 2021.
Ahold Delhaize will provide regular updates on the progress of the program by means of press releases. 

Cautionary notice

This communication includes forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Words such as commences, expects, complete, before, the end of, 2021, maintaining, growth, support, strategy, purpose, reduce, will, be, existing, if, progress or other similar words or expressions are typically used to identify forward-looking statements.

Forward-looking statements are subject to risks, uncertainties and other factors that are difficult to predict and that may cause actual results of Koninklijke Ahold Delhaize N.V. (the “Company”) to differ materially from future results expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risk factors set forth in the Company’s public filings and other disclosures. Forward-looking statements reflect the current views of the Company’s management and assumptions based on information currently available to the Company’s management. Forward-looking statements speak only as of the date they are made and the Company does not assume any obligation to update such statements, except as required by law.



Tiziana Life Sciences plc (“Tiziana” or the “Company”) – Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil


  • Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated

  • The scientific approaches underlying this clinical study could potentially be effective against SARs, MERS, and all variants of coronaviruses

  • This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses

NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the completion of its clinical study in Brazil investigating nasally administered Foralumab, its proprietary human monoclonal antibody, either alone or in combination with orally administered dexamethasone in COVID-19 patients.

The clinical study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), Santa Casa de Misericórdia de Santos Hospital (Santos, Brazil) and INTRIALS, a world-class, full-service Latin American CRO based in São Paulo, Brazil. The last patients in the trial received their final dose on 21 December 2020.

The topline data from the trial is expected to be available in January 2021.

Because COVID-19 enters through the nasal and respiratory passage, the proprietary nasal formulation and nasal delivery of Foralumab is an innovative approach to provide immediate relief to COVID-19 patients.

Dr. Howard Weiner (the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center, and Co-Director of the Ann Romney Center for Neurologic Diseases at the Brigham & Women’s Hospital) commented:

“Nasal administration of Foralumab to modulate the human immune system is a potentially transformative approach for treating patients with a variety of human diseases with dysregulated immune systems. Preclinical data from our laboratory have shown that the nasal administration of anti-CD3 stimulates Tregs that can suppress inflammation and ameliorate inflammatory diseases. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.”

Dr Thais Moreira, the lead scientist and coordinator of the clinical trial, stated:

“We are delighted to receive positive feedback from patients treated in the clinical trial. Among the positive results patients reported, the most common was that the treatment resulted in the rapid improvement in smell sensation, which is frequently lost in COVID-19 patients.”

Dr. Kimble Matos, the lead coordinating physician of the study, commented:

“The observations made during the Clinical study did not show any adverse events.”

The clinical study enrolled a total of 39 patients with moderate to severe COVID-19 who did not require the use of a ventilator at the beginning of the study. This study had three cohorts: control (n=16), nasally administered Foralumab (n=12), and nasally administered Foralumab with 3 days of priming with orally administered 6 mg dexamethasone (n=11).

  • The primary endpoint of this study was safety of the treatment, and secondary endpoints were to evaluate the effect of treatment on disease severity symptoms, nasal tolerance, sense of smell, and biomarkers for disease progression. The pharmacokinetics of nasally administered Foralumab will also be evaluated.
  • Patient reported outcome to assess clinical responses related to COVID-19 symptoms, as per the FDA guidelines, will also be collected.

Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences, commented:

“While we expect to get the topline data in January 2021, we are delighted with the positive feedback received from the treated patients. This is the first-in-class and scientifically logical approach to improve the human immune system by stimulating Tregs to suppress lung inflammation, and to dampen cytotoxic CD8+ T cell responses in the nasal and respiratory tract, the primary sites of the COVID-19 virus.

“We believe this approach could potentially provide benefits to patients already infected with COVID-19 and its newly identified variants. Thus, our therapeutic approach to provide rapid relief to patients already suffering with the diseases is particularly important, because vaccination is primarily to prevent COVID-19 infection, but it may not be useful for treatment of COVID-19 patients.”

A further announcement will be made in due course.

The person who arranged for the release of this announcement on behalf of the Company was Dr Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer of the Company.

About Foralumab

Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients with Crohn’s disease with decreases in the classic side effects of cytokine release syndrome (CRS) and improves the overall safety profile of Foralumab. In a humanized mouse model (NOD/SCID IL2γc-/-), it was shown that whilst targeting the T cell receptor, orally administered Foralumab modulates immune responses of the T cells, enhances regulatory T-cells (Tregs) and thus provides therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy (Ogura M. et al., 2017). Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of Tregs.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn’s Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

For further enquiries:

United Kingdom:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder 
+44 (0)20 7495 2379

United States:

Investors:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
[email protected]

 



Mkango Announces Warrant Transactions by Talaxis and Non-Executive Director

LONDON and VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) — Mkango Resources Ltd. (AIM/TSX-V: MKA) (the “Company” or “Mkango”) is pleased to announce the following events:

Talaxis Warrant Exercise

With the objective of minimising dilution to Mkango shareholders, Talaxis Limited (“Talaxis”) has agreed with Mkango to amend the terms of a warrant held by Talaxis (the “Warrant”) to enable a cashless exercise. Under this amendment Talaxis has agreed to a cashless exercise of the Warrant for 1,000,000 common shares (“New Shares”) in lieu of payment for 12,000,000 Shares at 6.6 pence. The Warrant was due to expire on 31 December 2020. This amendment significantly reduces the dilution to other Mkango shareholders and avoids the Company issuing 12,000,000 shares at a significant discount to the current market price of Mkango Shares. The amendment of the Warrant and the issuance of the New Shares remain subject to TSX-V acceptance.

Following the issuance of the Shares to Talaxis pursuant to the amended Warrant and taking into account the warrant exercise below, Talaxis will increase its ownership of Mkango from 14,285,715 shares to 15,285,715 shares post-Warrant exercise, representing an increase from 10.7% to 11.3% of the issued and outstanding shares. Talaxis maintains its 49% ownership in the Songwe Hill Rare Earths Project (the “Project”) and its option to acquire a further 26% interest in the Project by arranging financing for project development including funding the equity component thereof.            

Talaxis is a substantial shareholder in Mkango and is therefore a related party as defined by the AIM Rules for Companies. The amendment to the terms of the Warrant is a related party transaction for the purposes of AIM Rule 13 of the AIM Rules for Companies. The directors of Mkango consider, having consulted with the Company’s Nominated Adviser, SP Angel Corporate Finance LLP, that the terms of the related party transaction are fair and reasonable insofar as its shareholders are concerned.

Non-Executive Director Warrant Exercise

Mr. Shaun Treacy, non-executive director of Mkango, has exercised warrants for 1,200,000 New Shares at a price of 6.6 pence each, for total proceeds to Mkango of £79,200 (US$107,000). Following the warrant exercise, Mr. Treacy will own a 1.4% interest in Mkango.

After these two transactions, there are no further warrants outstanding.

William Dawes, Chief Executive of Mkango stated:
“The cashless warrant exercise agreed with Talaxis minimises potential dilution to other Mkango shareholders as the Company enters a transformational period of growth, with anticipated 2021 news flow including results from the ongoing feasibility study for the Songwe Hill rare earths project and the recently completed rutile exploration programme in Malawi, and developments in relation to Maginito and its interest in UK rare earth magnet recycler, HyProMag. Furthermore, the warrant exercise by non-executive director, Shaun Treacy, demonstrates confidence in the Company and the market outlook. With the growing global demand for critical materials related to electric vehicles and wind power, Mkango is uniquely positioned in the rare earths sector, where we anticipate increasing market focus and corporate activity.

The New Shares issued Pursuant to the warrant exercises, will rank pari passu with the existing common shares. Application has been made for the New Shares issued to Mr Treacy to be admitted to trading on AIM (“Admission”). It is expected that Admission will become effective and dealings in the Shares will commence on or around January 8, 2021. The New Shares will also trade on the TSX-V.

In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6.1R) the Company hereby notifies the market that immediately following Admission of the New Shares to Mr Treacy, its issued share capital will consist of 134,200,721 shares. The Company does not hold any shares in treasury. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

Following receipt of TSX-V approval for the amendment to the terms of the Warrant and the issue of the 1,000,000 Shares to Talaxis, application will be made for these New Shares to be admitted to trading on AIM. A further announcement will be made at such time.

A
bou
t
M
k
an
go

Mkango’s primary business is exploration for rare earth elements and associated minerals in the Republic of Malawi, a country whose hospitable people have earned it a reputation as “the warm heart of Africa”. The Company holds interests in four exclusive prospecting licenses in Malawi: the Phalombe licence, the Thambani licence, the Chimimbe Hill licence and the Mchinji licence.

The main exploration target in the 51% held Phalombe licence is the Songwe Hill rare earths deposit. This features carbonatite-hosted rare earth mineralisation and was subject to previous exploration in the late 1980s. Mkango completed an updated Pre-Feasibility Study for the project in November 2015 and a Feasibility Study is currently underway, the initial phases of which included a 10,900 metre drilling programme and an updated mineral resource estimate, announced in February 2019. In March 2019, the Company announced receipt of a £7 million (C$12.3 million) investment from Talaxis to fund completion of the Feasibility Study. Following completion of the Feasibility Study, Talaxis has an option to acquire a further 26% interest in Songwe by arranging financing for project development including funding the equity component thereof.

The main exploration targets in Mkango’s remaining three 100% held licences are, in the Thambani licence, uranium, niobium, tantalum and zircon, in the Chimimbe Hill licence, nickel and cobalt, and in the Mchinji licence, rutile, nickel, cobalt, base metals and graphite. Mkango recently completed an extensive exploration program following a new rutile discovery within the Mchinji licence.

Mkango also holds a 75.5% interest in Maginito (www.maginito.com) with the balance owned by Talaxis. Maginito was established by Mkango and Talaxis to pursue downstream green technology opportunities in the rare earths supply chain, encompassing neodymium (NdFeB) magnet recycling as well as innovative rare earth alloy, magnet and separation technologies.

Maginito’s strategy is underpinned by offtake rights for sustainably sourced primary and secondary raw materials, and geared to accelerating growth in the electric vehicle sector, wind power generation and other industries driven by decarbonization of the economy.

For more information, please visit www.mkango.ca.

About Talaxis

Founded in 2016, Talaxis is a wholly-owned subsidiary of Noble Group Holdings Limited and invests in and develops projects that are related to technology metals, with a special focus on rare earth elements. Talaxis focuses on battery and electric vehicle materials such as nickel, lithium, graphite and vanadium. Talaxis has supply chain partners in the upstream and midstream segments, and also focuses on research and development solutions for industrial consumers in the downstream segment. Talaxis prioritises sustainable ventures with a strong emphasis on corporate social responsibility. These include projects that contribute to the decarbonisation of the economy and that are aligned with the United Nations Sustainable Development Goals.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement may have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements (within the meaning of that term under applicable securities laws) with respect to Mkango, its business and the Project. Generally, forward looking statements can be identified by the use of words such as “plans”, “expects” or “is expected”, “scheduled”, “estimates” “intends”, “anticipates”, “believes”, or variations of such words and phrases, or statements that certain actions, events or results “can”, “may”, “could”, “would”, “should”, “might” or “will”, occur or be achieved, or the negative connotations thereof. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. Such factors and risks include, without limiting the foregoing, governmental action relating to COVID-19, COVID-19 and other market effects on global demand for the metals and associated downstream products for which Mkango is exploring, researching and developing, the positive results of a feasibility study on the Project and delays in obtaining financing or governmental or stock exchange approvals. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

For further information on Mkango, please contact:

Mkango Resources Limited  
William Dawes Alexander Lemon
Chief Executive Officer President

[email protected]

[email protected]
Canada: +1 403 444 5979  
   

www.mkango.ca
 
@MkangoResources  
   
Blytheweigh  
Financial Public Relations  
Tim Blythe  
UK: +44 207 138 3204  
   
SP Angel Corporate Finance LLP  
Nominated Adviser and Joint Broker  
Jeff Keating, Caroline Rowe  
UK: +44 20 3470 0470  
   
Alternative Resource Capital  
Joint Broker  
Alex Wood  
UK: +44 20 7186 9004  
   
Bacchus Capital Advisers  
Strategic and Financial Adviser  
Richard Allan  
UK: +44 20 3848 1642  


The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any equity or other securities of the Company in the United States. The securities of the Company will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold within the United States to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act.



Caledonia declares fourth increased quarterly dividend in five quarters

ST HELIER, Jersey, Jan. 04, 2021 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or the “Company”) (NYSE AMERICAN: CMCL; AIM: CMCL) is pleased to announce that the Board of Directors has declared an increased quarterly dividend of eleven United States cents (US$0.11) on each of the Company’s shares.

Highlights

  • 10% increase from the previous quarterly dividend of 10 cents that was paid in October 2020.
  • 60% cumulative increase from the level of 6.875 cents since October 2019.
  • 4th increase in the quarterly dividend since October 2019.
  • Central Shaft scheduled to be commissioned during the first quarter of 2021.
  • Target production of 61,000 to 67,000 ounces of gold in 2021; target production of 80,000 ounces of gold per annum from 2022.1
  • Increasing production, a high gold price and good cost control have continued to result in increased cash generation which has given the Board confidence that the business can sustain a higher level of dividend distributions before the benefits of Central Shaft are realised.

Commenting on the announcement, Steve Curtis, Chief Executive Officer, said:

“We are pleased to announce an additional 10 per cent increase in our quarterly dividend, the fourth increase in the past 15 months representing a cumulative 60 per cent rise in the dividend since the first increase in October 2019. The decision by the Board to increase the dividend reflects our continued and increasing confidence in the outlook for our business. As we reported in our third quarter 2020 results, the business continues to perform well supported by strong production and a firm gold price.

“As we approach the end of the six-year investment programme at Blanket Mine, we expect the combination of rising production and declining capital investment over the next two years will give us the scope to consider further increases in the dividend in addition to providing funding for investment in new projects, including the exploration prospects at Glen Hume and Connemara North as announced on 10 and 17 December 2020, respectively.”

The relevant dates relating to the dividend are as follows:

  • Ex-dividend date: January 14, 2021
  • Record date: January 15, 2021
  • Dividend cheque mailing date: January 29, 2021

Shareholders with a registered address in the UK will be paid in Sterling.

Caledonia’s Dividend Policy

Caledonia’s strategy to maximise shareholder value includes a quarterly dividend policy which the Board adopted in 2014. The Board will consider future increases in the dividend as appropriate in line with its prudent approach to risk management.

For further information please contact:

Caledonia Mining Corporation Plc

Mark Learmonth
Camilla Horsfall
Tel: +44 1534 679 802
Tel: +44 7817 841793
   
WH Ireland

Adrian Hadden/James Sinclair-Ford
Tel: +44 20 7220 1751
   
Blytheweigh

Tim Blythe/Megan Ray
Tel: +44 207 138 3204
   
3PPB

Patrick Chidley
Paul Durham
Tel: +1 917 991 7701
Tel: +1 203 940 2538

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation (EU) No. 596/2014.

Cautionary Note Concerning Forward-Looking Information

Information and statements contained in this news release that are not historical facts are “forward-looking information” within the meaning of applicable securities legislation that involve risks and uncertainties relating, but not limited to Caledonia’s current expectations, intentions, plans, and beliefs. Forward-looking information can often be identified by forward-looking words such as “anticipate”, “believe”, “expect”, “goal”, “plan”, “target”, “intend”, “estimate”, “could”, “should”, “may” and “will” or the negative of these terms or similar words suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance. Examples of forward-looking information in this news release include: production guidance, estimates of future/targeted production rates, and our plans and timing regarding further exploration and drilling and development. This forward-looking information is based, in part, on assumptions and factors that may change or prove to be incorrect, thus causing actual results, performance or achievements to be materially different from those expressed or implied by forward-looking information. Such factors and assumptions include, but are not limited to: failure to establish estimated resources and reserves, the grade and recovery of ore which is mined varying from estimates, success of future exploration and drilling programs, reliability of drilling, sampling and assay data, assumptions regarding the representativeness of mineralization being inaccurate, success of planned metallurgical test-work, capital and operating costs varying significantly from estimates, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects and other factors.

Security holders, potential security holders and other prospective investors should be aware that these statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. Such factors include, but are not limited to: risks relating to estimates of mineral reserves and mineral resources proving to be inaccurate, fluctuations in gold price, risks and hazards associated with the business of mineral exploration, development and mining, risks relating to the credit worthiness or financial condition of suppliers, refiners and other parties with whom the Company does business; inadequate insurance, or inability to obtain insurance, to cover these risks and hazards, employee relations; relationships with and claims by local communities and indigenous populations; political risk; risks related to natural disasters, terrorism, civil unrest, public health concerns (including health epidemics or outbreaks of communicable diseases such as the coronavirus (COVID-19)); availability and increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development, including the risks of obtaining or maintaining necessary licenses and permits, diminishing quantities or grades of mineral reserves as mining occurs; global financial condition, the actual results of current exploration activities, changes to conclusions of economic evaluations, and changes in project parameters to deal with unanticipated economic or other factors, risks of increased capital and operating costs, environmental, safety or regulatory risks, expropriation, the Company’s title to properties including ownership thereof, increased competition in the mining industry for properties, equipment, qualified personnel and their costs, risks relating to the uncertainty of timing of events including targeted production rate increase and currency fluctuations. Security holders, potential security holders and other prospective investors are cautioned not to place undue reliance on forward-looking information. By its nature, forward-looking information involves numerous assumptions, inherent risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and various future events will not occur. Caledonia undertakes no obligation to update publicly or otherwise revise any forward-looking information whether as a result of new information, future events or other such factors which affect this information, except as required by law.



________________________
1

Mr
Dana Roets (B
Eng
(Min.), MBA,
Pr.Eng
., FSAIMM, AMMSA), Chief Operating Officer, is the Company’s qualified person as defined by Canada’s National Instrument 43-101 and has approved any scientific or technical information contained in this news release.